sun pharma semaglutide Day 1, patent expiry: Pharma, Zydus Lifesciences launch generic versions Sun Pharma receives approval to

Indications and Contraindications: Indications include individuals with a body mass index (BMI) of 30 or higher or those with a BMI of at least 27 with one or more weight-related comorbidities, such as hypertension or type 2 diabetes

Whilst this is generally well-tolerated, donation services assess cardiovascular stability, and any significant tachycardia or blood pressure abnormalities would warrant deferral

Every documented case of semaglutide-associated allodynia has resolved either with medication discontinuation, dose reduction, or spontaneously over weeks to months while continuing the medication

Best for: Mild to moderate weight loss goals People already making lifestyle changes 2

Garza is a board certified plastic surgeon practicing in middle Tennessee since 2009